A pharmaceutical composition for treating multidrug-resistant bacterial infection and its application
By combining photoglyceridine with polymyxin, as a polymyxin efflux pump inhibitor, the resistance of multidrug-resistant bacteria to polymyxin is solved, and the antibacterial effect is significantly improved. An effective pharmaceutical composition for the treatment of multidrug-resistant bacteria infection.
Patent Information
- Application Number
- CN202211029794.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-08-25
- Publication Date
- 2024-11-05
- Estimated Expiration
- 2042-08-25
AI Technical Summary
The hospital infection rate caused by multidrug-resistant bacteria is increased, especially the drug resistance of multidrug-resistant bacteria to polymyxins is serious, and it is difficult for the existing technology to effectively treat drug-resistant bacteria infection.
Photoglyceridine is used in combination with polymyxin. Photoglyceridine is used as a polymyxin efflux pump inhibitor to reduce the minimum inhibitory concentration of drug-resistant bacteria and enhance the antibacterial effect of polymyxin.
The resistance of drug-resistant bacteria to polymyxins is significantly reduced, the antibacterial effect of polymyxins on drug-resistant bacteria is improved, and a drug composition for effective treatment of multidrug-resistant bacteria infection is provided.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of biomedicine and relates to a pharmaceutical composition for treating multi-drug resistant bacterial infection and application thereof. Background Art
[0002] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention, and should not necessarily be regarded as an admission or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.
[0003] Polymyxin is a "special use drug" in the hierarchical management of antimicrobial drugs and is clinically used to treat severe infections caused by multidrug-resistant Gram-negative bacteria. However, the rate of hospital infections caused by multidrug-resistant bacteria has increased year by year in recent years, especially the increasingly serious polymyxin resistance of multidrug-resistant bacteria, which poses a severe challenge to the clinical treatment of multidrug-resistant bacterial infections. Therefore, screening for potentiators that can effectively treat drug-resistant bacterial infections without increasing the dose of polymyxin has important clinical application value. Summary of the invention
[0004] In order to address the deficiencies of the prior art, the purpose of the present invention is to provide a pharmaceutical composition for treating multidrug-resistant bacterial infections and its use, which can effectively kill polymyxin-resistant bacteria and is expected to be applied to the clinical treatment of multidrug-resistant bacterial infections.
[0005] In order to achieve the above object, the technical solution of the present invention is:
[0006] In one aspect, a use of glabridin in the preparation of or as a polymyxin efflux pump inhibitor.
[0007] The structural formula of glabridin is as follows:
[0008]
[0009] According to the inventor's research, glabridin can eliminate free radicals and melanin in the skin. Because of its powerful whitening effect, it is known as "whitening gold", so it is generally used as a cosmetic raw material. The present invention unexpectedly found that glabridin can be used as a polymyxin efflux pump inhibitor for combined use with polymyxin to treat multidrug-resistant bacterial infections. Adding glabridin to various polymyxin preparations can significantly reduce the minimum inhibitory concentration of drug-resistant bacteria and enhance the antibacterial effect of polymyxin on drug-resistant bacteria.
[0010] Since glabridin has a synergistic effect when used in combination with polymyxin antibiotics, polymyxin-resistant bacteria can be effectively killed. Therefore, on the other hand, a use of glabridin in the preparation or as a synergist of polymyxin antibiotics.
[0011] In a third aspect, a pharmaceutical composition for treating multidrug-resistant bacterial infection comprises polymyxin and glabridin.
[0012] In some embodiments, the mass ratio of polymyxin to glabridin is 0.1 to 20:1.
[0013] In some embodiments, the polymyxin is polymyxin B and / or polymyxin E.
[0014] In a fourth aspect, a drug for multidrug-resistant bacterial infection comprises an active ingredient and a pharmaceutically acceptable excipient, wherein the active ingredient is the above-mentioned pharmaceutical composition for multidrug-resistant bacterial infection.
[0015] The pharmaceutically acceptable excipients of the present invention include carriers, excipients, etc. The carriers include aluminum oxide, aluminum stearate, polyvinyl pyrrolidone, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylate, beeswax, lanolin, etc. The excipients include adhesives, fillers, lubricants, disintegrants, wetting agents, etc. The adhesives include syrup, gum arabic, sorbitol, etc. The fillers include lactose, corn starch, aminoacetic acid, etc. The lubricants include magnesium stearate, talc, silica, etc. The wetting agents include sodium lauryl sulfate, etc.
[0016] In some embodiments, the dosage form is an oral dosage form or a non-oral dosage form. The oral dosage form includes tablets, capsules, dripping pills, solutions, granules, etc. Non-oral dosage forms include ointments, injections, etc.
[0017] A fifth aspect provides a use of the above-mentioned pharmaceutical composition for multidrug-resistant bacterial infection or a drug for multidrug-resistant bacterial infection in the preparation of a drug for treating bacterial infection.
[0018] In some embodiments, the bacteria are multi-drug resistant bacteria, and the multi-drug resistant bacteria are drug-resistant Enterobacter cloacae and / or drug-resistant Stenotrophomonas.
[0019] The beneficial effects of the present invention are:
[0020] The present invention has experimentally found that glabridin can be used as a polymyxin efflux pump inhibitor for combined use with polymyxin to treat multidrug-resistant bacterial infections. Adding glabridin to various polymyxin preparations can significantly reduce the minimum inhibitory concentration of drug-resistant bacteria and enhance the antibacterial effect of polymyxin on drug-resistant bacteria. The present invention provides a strategy for the combined use of glabridin and polymyxin to maintain the efficacy of polymyxin, and has important drug research and development and clinical application value. DETAILED DESCRIPTION
[0021] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.
[0022] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit exemplary embodiments according to the present invention. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprising" and / or "including" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.
[0023] In order to enable those skilled in the art to more clearly understand the technical solution of the present invention, the technical solution of the present invention will be described in detail below in conjunction with specific embodiments.
[0024] Example 1
[0025] When polymyxin E and glabridin are used in combination, they have a synergistic inhibitory effect against multidrug-resistant bacteria.
[0026] In this example, the multidrug-resistant strains Enterobacter cloacae POL9 and Stenotrophomonas sp. G4 were isolated and stored in the laboratory, polymyxin E sulfate CAS: 1264-72-8 (potency 19000 IU / mg) was purchased from Sigma, and glabridin CAS: 59870-68-7 (purity ≥ 99%) was purchased from Shanghai MacLean Biochemical Technology Co., Ltd.
[0027] Polymyxin E sulfate was prepared into a 32 mg / mL stock solution with sterile water and sterilized by filtration with a 0.22 μm filter membrane. Glabridin was prepared into a 5 mM stock solution with DMSO and sterilized by filtration with a 0.22 μm filter membrane.
[0028] According to the CLSI regulations, the minimum inhibitory concentrations (MICs) of polymyxin E, glabridin, and the combination of polymyxin E and glabridin against multidrug-resistant bacteria POL9 and G4 were determined by microbroth dilution method. The results are shown in Table 1. The MICs of POL9 strain and G4 strain to polymyxin E were 96 mg / L and >128 mg / L, respectively, and they were tolerant to glabridin. The addition of 2 mg / L glabridin significantly reduced the MICs of POL9 strain and G4 strain to polymyxin E, indicating that polymyxin E and glabridin have a synergistic inhibitory effect on multidrug-resistant bacteria when used in combination.
[0029] Table 1 MICs (mg / L) of multidrug-resistant bacteria
[0030]
[0031] Example 2
[0032] Glabridin inhibits the resistance function of polymyxin resistance genes.
[0033] Preliminary studies have confirmed that one of the polymyxin resistance genes in POL9 is LMJ45_RS21145 / LMJ45_RS21150, and one of the polymyxin resistance genes in the G4 strain is D0Y85_RS16900 / D0Y85_RS16905. The polymyxin resistance gene in the above-mentioned POL9 strain (primer F: aatattgaaaaaggaagagtatgacgaatcatttcagacg, as shown in SEQ ID NO.1, R: tcactctttatggcgcgtaa, as shown in SEQ ID NO.2) and G4 strain (primer F: tcggggctggcttaatcggccgggcggctgcccgg, as shown in SEQ ID NO.3, R: cacaggaaacagctagaggttcaaatccagcgcag, as shown in SEQ ID NO.4) was amplified by overlapping PCR, connected to the downstream of the Escherichia coli promoter, and the recombinant vector was transformed into the Escherichia coli DH5α strain after sequencing verification to obtain heterologous expression recombinant strains P21145 and G16900. MIC detection showed that the polymyxin MIC values of P21145 (resistance gene derived from POL9 strain) and G16900 (resistance gene derived from G4 strain) were 64 mg / L and 48 mg / L, respectively (Table 2), while the polymyxin MIC value of the starting strain DH5α was <2 mg / L, and the MIC value of glabridin was >128 mg / L. When 2 mg / L-10 mg / L glabridin was added, the polymyxin MIC values of P21145 and G16900 strains decreased significantly, reaching a minimum of <2 mg / L, indicating sensitivity to polymyxin.
[0034] Table 2 MICs of polymyxin E and glabridin (mg / L)
[0035]
[0036] Example 3
[0037] Effect of colistin and glabridin combined in the treatment of acute peritonitis in mice.
[0038] The acute peritonitis model of mice was established by intraperitoneal injection of P21145 and G16900 strains. The drug-treated group was injected with polymyxin E (0.1 mg) or polymyxin E + glabridin (0.1 mg + 0.2 mg) twice a day, and the non-administered group was injected with an equal volume of normal saline. Then, the peritoneal fluid was extracted at 24 hours, 48 hours, and 72 hours for bacterial culture, identification, and counting. At the same time, the tail vein blood was taken to count the total number of peripheral blood leukocytes to observe the anti-infection therapeutic effect of the combined use of glabridin and polymyxin. The results showed that the bacterial infection had been cleared in the polymyxin and glabridin combined administration group at 72 hours, no bacteria were detected in the peritoneal fluid, and the total number of peripheral blood leukocytes was within the normal range (Table 3). However, the group that was administered with polymyxin E alone or without drug administration still showed symptoms of peritonitis at 72 hours, and a few experimental mice died.
[0039] Table 3 Counts of bacteria in peritoneal fluid and peripheral blood leukocytes in each group of mice at 72 hours
[0040]
[0041] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A pharmaceutical composition for treating multidrug-resistant bacterial infection, characterized in that: for polymyxin and glabridin; The mass ratio of polymyxin to glabridin is 0.1~20:1; The polymyxin is polymyxin E.
2. A drug for treating multidrug-resistant bacterial infection, comprising an active ingredient and a pharmaceutically acceptable excipient, characterized in that: The active ingredient is the pharmaceutical composition for treating multidrug-resistant bacterial infection as described in claim 1.
3. The drug for treating multidrug-resistant bacterial infection according to claim 2, characterized in that: The pharmaceutically acceptable auxiliary materials are carriers and / or excipients.
4. The drug for treating multidrug-resistant bacterial infection according to claim 2, characterized in that: The dosage form is oral or parenteral.
5. Use of the pharmaceutical composition for treating multidrug-resistant bacterial infection according to claim 1 or the drug for treating multidrug-resistant bacterial infection according to any one of claims 2 to 4 in the preparation of a drug for treating bacterial infection; The bacteria are Enterobacter cloacae POL9 and / or Stenotrophomonas sp. G4.
